Authors: Baxter, GF Mocanu, MM Brar, BK Latchman, DS Yellon, DM

Citation: Gf. Baxter et al., Cardioprotective effects of transforming growth factor-beta 1 during earlyreoxygenation or reperfusion are mediated by p42/p44 MAPK, J CARDIO PH, 38(6), 2001, pp. 930-939

Authors: Mocanu, MM Maddock, HL Baxter, GF Lawrence, CL Standen, NB Yellon, DM

Citation: Mm. Mocanu et al., Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide, CIRCULATION, 103(25), 2001, pp. 3111-3116

Authors: Mocanu, MM Baxter, GF Yue, Y Critz, SD Yellon, DM

Citation: Mm. Mocanu et al., The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical, BAS R CARD, 95(6), 2000, pp. 472-478

Authors: Mocanu, MM Baxter, GF Yellon, DM

Citation: Mm. Mocanu et al., Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury, BR J PHARM, 130(2), 2000, pp. 197-200

Authors: Mocanu, MM Gadgil, S Yellon, DM Baxter, GF

Citation: Mm. Mocanu et al., Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism, CARDIO DRUG, 13(2), 1999, pp. 115-122